Is HZD or FARN more profitable?

Faron Pharmaceuticals Oy's return on equity of 45.13% beat Horizon Discovery Group plc (HZD.L)'s return on equity. Company Net Margins Return on Equity Return on Assets Horizon Discovery Group plc (HZD.L) N/A N/A N/A Faron Pharmaceuticals Oy N/A 45.13% -70.00%

Do analysts prefer PRTC or FARN?

PureTech Health currently has a consensus target price of GBX 508, suggesting a potential upside of 312.34%. Given PureTech Health's stronger consensus rating and higher possible upside, equities analysts plainly believe PureTech Health is more favorable than Faron Pharmaceuticals Oy. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PureTech Health 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Faron Pharmaceuticals Oy 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable valuation and earnings, FARN or VRP?

Faron Pharmaceuticals Oy is trading at a lower price-to-earnings ratio than Verona Pharma plc (VRP.L), indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Faron Pharmaceuticals Oy N/A N/A -£60.23M -£22.07 N/A Verona Pharma plc (VRP.L) N/A N/A N/A -£32.70 N/A

Is FARN or VRP more profitable?

Faron Pharmaceuticals Oy's return on equity of 45.13% beat Verona Pharma plc (VRP.L)'s return on equity. Company Net Margins Return on Equity Return on Assets Faron Pharmaceuticals Oy N/A 45.13% -70.00% Verona Pharma plc (VRP.L) N/A N/A N/A

Do analysts rate BTG or FARN?

BTG currently has a consensus target price of GBX 160, suggesting a potential upside of 48.84%. Given BTG's stronger consensus rating and higher possible upside, equities analysts plainly believe BTG is more favorable than Faron Pharmaceuticals Oy. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BTG 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Faron Pharmaceuticals Oy 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is BTG or FARN more profitable?

Faron Pharmaceuticals Oy's return on equity of 45.13% beat BTG's return on equity. Company Net Margins Return on Equity Return on Assets BTG N/A N/A N/A Faron Pharmaceuticals Oy N/A 45.13% -70.00%

Faron Pharmaceuticals Oy (FARN) Competitors

GBX 38.10 -3.52 (-8.46%)

As of 12:20 PM Eastern

Compare

FARN vs. HZD, PRTC, VRP, BTG, and ARIX

Should you buy Faron Pharmaceuticals Oy stock or one of its competitors? MarketBeat compares Faron Pharmaceuticals Oy with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Faron Pharmaceuticals Oy include Horizon Discovery Group plc (HZD.L) (HZD), PureTech Health (PRTC), Verona Pharma plc (VRP.L) (VRP), BTG (BTG), and Arix Bioscience (ARIX). These companies are all part of the "biotechnology" industry.

How does Faron Pharmaceuticals Oy compare to Horizon Discovery Group plc (HZD.L)?

Horizon Discovery Group plc (HZD.L) (LON:HZD) and Faron Pharmaceuticals Oy (LON:FARN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, earnings, institutional ownership, media sentiment and dividends.

Faron Pharmaceuticals Oy's return on equity of 45.13% beat Horizon Discovery Group plc (HZD.L)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Horizon Discovery Group plc (HZD.L)	N/A	N/A	N/A
Faron Pharmaceuticals Oy	N/A	45.13%	-70.00%

2.5% of Faron Pharmaceuticals Oy shares are held by institutional investors. 2.7% of Faron Pharmaceuticals Oy shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Horizon Discovery Group plc (HZD.L) has higher revenue and earnings than Faron Pharmaceuticals Oy. Faron Pharmaceuticals Oy is trading at a lower price-to-earnings ratio than Horizon Discovery Group plc (HZD.L), indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Horizon Discovery Group plc (HZD.L)	£54.63M	0.00	N/A	-£5.50	N/A
Faron Pharmaceuticals Oy	N/A	N/A	-£60.23M	-£22.07	N/A

In the previous week, Horizon Discovery Group plc (HZD.L)'s average media sentiment score of 0.00 equaled Faron Pharmaceuticals Oy'saverage media sentiment score.

Company	Overall Sentiment
Horizon Discovery Group plc (HZD.L)	Neutral
Faron Pharmaceuticals Oy	Neutral

Summary

Faron Pharmaceuticals Oy beats Horizon Discovery Group plc (HZD.L) on 4 of the 7 factors compared between the two stocks.

How does Faron Pharmaceuticals Oy compare to PureTech Health?

PureTech Health (LON:PRTC) and Faron Pharmaceuticals Oy (LON:FARN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, media sentiment, institutional ownership, earnings and profitability.

PureTech Health has a beta of 0.793, indicating that its stock price is 21% less volatile than the broader market. Comparatively, Faron Pharmaceuticals Oy has a beta of 1.12, indicating that its stock price is 12% more volatile than the broader market.

33.5% of PureTech Health shares are held by institutional investors. Comparatively, 2.5% of Faron Pharmaceuticals Oy shares are held by institutional investors. 13.3% of PureTech Health shares are held by insiders. Comparatively, 2.7% of Faron Pharmaceuticals Oy shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, PureTech Health had 6 more articles in the media than Faron Pharmaceuticals Oy. MarketBeat recorded 6 mentions for PureTech Health and 0 mentions for Faron Pharmaceuticals Oy. PureTech Health's average media sentiment score of 1.63 beat Faron Pharmaceuticals Oy's score of 0.00 indicating that PureTech Health is being referred to more favorably in the media.

Company	Overall Sentiment
PureTech Health	Very Positive
Faron Pharmaceuticals Oy	Neutral

Faron Pharmaceuticals Oy has lower revenue, but higher earnings than PureTech Health. PureTech Health is trading at a lower price-to-earnings ratio than Faron Pharmaceuticals Oy, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PureTech Health	£4.66M	64.37	-£91.86M	-£46.00	N/A
Faron Pharmaceuticals Oy	N/A	N/A	-£60.23M	-£22.07	N/A

PureTech Health currently has a consensus target price of GBX 508, suggesting a potential upside of 312.34%. Given PureTech Health's stronger consensus rating and higher possible upside, equities analysts plainly believe PureTech Health is more favorable than Faron Pharmaceuticals Oy.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PureTech Health	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Faron Pharmaceuticals Oy	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Faron Pharmaceuticals Oy has a net margin of 0.00% compared to PureTech Health's net margin of -2,355.32%. Faron Pharmaceuticals Oy's return on equity of 45.13% beat PureTech Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PureTech Health	-2,355.32%	-31.98%	-13.39%
Faron Pharmaceuticals Oy	N/A	45.13%	-70.00%

Summary

PureTech Health beats Faron Pharmaceuticals Oy on 9 of the 15 factors compared between the two stocks.

How does Faron Pharmaceuticals Oy compare to Verona Pharma plc (VRP.L)?

Faron Pharmaceuticals Oy (LON:FARN) and Verona Pharma plc (VRP.L) (LON:VRP) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, profitability, risk, earnings and dividends.

Faron Pharmaceuticals Oy's return on equity of 45.13% beat Verona Pharma plc (VRP.L)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Faron Pharmaceuticals Oy	N/A	45.13%	-70.00%
Verona Pharma plc (VRP.L)	N/A	N/A	N/A

2.5% of Faron Pharmaceuticals Oy shares are owned by institutional investors. 2.7% of Faron Pharmaceuticals Oy shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Faron Pharmaceuticals Oy's average media sentiment score of 0.00 equaled Verona Pharma plc (VRP.L)'saverage media sentiment score.

Company	Overall Sentiment
Faron Pharmaceuticals Oy	Neutral
Verona Pharma plc (VRP.L)	Neutral

Faron Pharmaceuticals Oy is trading at a lower price-to-earnings ratio than Verona Pharma plc (VRP.L), indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Faron Pharmaceuticals Oy	N/A	N/A	-£60.23M	-£22.07	N/A
Verona Pharma plc (VRP.L)	N/A	N/A	N/A	-£32.70	N/A

Summary

Faron Pharmaceuticals Oy beats Verona Pharma plc (VRP.L) on 4 of the 6 factors compared between the two stocks.

How does Faron Pharmaceuticals Oy compare to BTG?

BTG (LON:BTG) and Faron Pharmaceuticals Oy (LON:FARN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings.

In the previous week, BTG had 7 more articles in the media than Faron Pharmaceuticals Oy. MarketBeat recorded 7 mentions for BTG and 0 mentions for Faron Pharmaceuticals Oy. Faron Pharmaceuticals Oy's average media sentiment score of 0.00 beat BTG's score of -0.17 indicating that Faron Pharmaceuticals Oy is being referred to more favorably in the news media.

Company	Overall Sentiment
BTG	Neutral
Faron Pharmaceuticals Oy	Neutral

19.2% of BTG shares are held by institutional investors. Comparatively, 2.5% of Faron Pharmaceuticals Oy shares are held by institutional investors. 19.7% of BTG shares are held by insiders. Comparatively, 2.7% of Faron Pharmaceuticals Oy shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

BTG currently has a consensus target price of GBX 160, suggesting a potential upside of 48.84%. Given BTG's stronger consensus rating and higher possible upside, equities analysts plainly believe BTG is more favorable than Faron Pharmaceuticals Oy.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BTG	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Faron Pharmaceuticals Oy	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

BTG has higher revenue and earnings than Faron Pharmaceuticals Oy. Faron Pharmaceuticals Oy is trading at a lower price-to-earnings ratio than BTG, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BTG	£159.40M	1.09	N/A	£6.00	17.92
Faron Pharmaceuticals Oy	N/A	N/A	-£60.23M	-£22.07	N/A

Faron Pharmaceuticals Oy's return on equity of 45.13% beat BTG's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BTG	N/A	N/A	N/A
Faron Pharmaceuticals Oy	N/A	45.13%	-70.00%

Summary

BTG beats Faron Pharmaceuticals Oy on 10 of the 12 factors compared between the two stocks.

How does Faron Pharmaceuticals Oy compare to Arix Bioscience?

Faron Pharmaceuticals Oy (LON:FARN) and Arix Bioscience (LON:ARIX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, earnings, analyst recommendations and dividends.

Faron Pharmaceuticals Oy has a beta of 1.12, indicating that its share price is 12% more volatile than the broader market. Comparatively, Arix Bioscience has a beta of 1.05, indicating that its share price is 5% more volatile than the broader market.

Arix Bioscience has higher revenue and earnings than Faron Pharmaceuticals Oy. Faron Pharmaceuticals Oy is trading at a lower price-to-earnings ratio than Arix Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Faron Pharmaceuticals Oy	N/A	N/A	-£60.23M	-£22.07	N/A
Arix Bioscience	£14.16M	0.00	£14.96M	£0.11	N/A

2.5% of Faron Pharmaceuticals Oy shares are held by institutional investors. Comparatively, 41.3% of Arix Bioscience shares are held by institutional investors. 2.7% of Faron Pharmaceuticals Oy shares are held by company insiders. Comparatively, 20.7% of Arix Bioscience shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Arix Bioscience has a net margin of 105.64% compared to Faron Pharmaceuticals Oy's net margin of 0.00%. Faron Pharmaceuticals Oy's return on equity of 45.13% beat Arix Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Faron Pharmaceuticals Oy	N/A	45.13%	-70.00%
Arix Bioscience	105.64%	6.41%	2.18%

In the previous week, Faron Pharmaceuticals Oy's average media sentiment score of 0.00 equaled Arix Bioscience'saverage media sentiment score.

Company	Overall Sentiment
Faron Pharmaceuticals Oy	Neutral
Arix Bioscience	Neutral

Summary

Arix Bioscience beats Faron Pharmaceuticals Oy on 8 of the 10 factors compared between the two stocks.

Get Faron Pharmaceuticals Oy News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FARN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FARN vs. The Competition

Export

Metric	Faron Pharmaceuticals Oy	Biotechnology Industry	Medical Sector	LON Exchange
Market Cap	£77.30M	£517.61M	£7.06B	£2.84B
Dividend Yield	N/A	3.90%	2.68%	6.17%
P/E Ratio	-1.73	3.47	27.15	368.18
Price / Sales	N/A	6,436.17	526.88	84,612.72
Price / Cash	20.00	13.13	29.22	27.87
Price / Book	0.02	85.93	10.75	7.49
Net Income	-£60.23M	-£96.07M	£3.58B	£5.89B
7 Day Performance	-9.29%	-1.18%	-2.10%	-0.48%
1 Month Performance	-13.31%	2.45%	3.32%	-1.00%
1 Year Performance	-81.19%	60.93%	28.17%	61.74%

Faron Pharmaceuticals Oy Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FARN Faron Pharmaceuticals Oy	N/A	GBX 38.10 -8.5%	N/A	-79.5%	£77.30M	N/A	N/A	34	Positive News Gap Up
HZD Horizon Discovery Group plc (HZD.L)	N/A	N/A	N/A	N/A	£302.98M	£54.63M	N/A	416
PRTC PureTech Health	3.7713 of 5 stars	GBX 120.20 -3.2%	GBX 508 +322.6%	-7.1%	£292.59M	£4.66M	N/A	300	Positive News Analyst Forecast
VRP Verona Pharma plc (VRP.L)	N/A	N/A	N/A	N/A	£228M	N/A	N/A	22	Gap Up
BTG BTG	4.3226 of 5 stars	GBX 117 +2.6%	GBX 160 +36.8%	N/A	£188.50M	£159.40M	19.50	4,690	Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:FARN) was last updated on 7/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Faron Pharmaceuticals Oy (FARN) Competitors

FARN vs. HZD, PRTC, VRP, BTG, and ARIX

How does Faron Pharmaceuticals Oy compare to Horizon Discovery Group plc (HZD.L)?

Summary

How does Faron Pharmaceuticals Oy compare to PureTech Health?

Summary

How does Faron Pharmaceuticals Oy compare to Verona Pharma plc (VRP.L)?

Summary

How does Faron Pharmaceuticals Oy compare to BTG?

Summary

How does Faron Pharmaceuticals Oy compare to Arix Bioscience?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FARN vs. The Competition

Faron Pharmaceuticals Oy Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Faron Pharmaceuticals Oy (FARN) Competitors

FARN vs. HZD, PRTC, VRP, BTG, and ARIX

How does Faron Pharmaceuticals Oy compare to Horizon Discovery Group plc (HZD.L)?

Is HZD or FARN more profitable?

Do institutionals & insiders have more ownership in HZD or FARN?

Which has higher earnings and valuation, HZD or FARN?

Does the media refer more to HZD or FARN?

Summary

How does Faron Pharmaceuticals Oy compare to PureTech Health?

Which has more volatility & risk, PRTC or FARN?

Do insiders & institutionals hold more shares of PRTC or FARN?

Does the media prefer PRTC or FARN?

Which has higher valuation and earnings, PRTC or FARN?

Do analysts prefer PRTC or FARN?

Is PRTC or FARN more profitable?

Summary

How does Faron Pharmaceuticals Oy compare to Verona Pharma plc (VRP.L)?

Is FARN or VRP more profitable?

Do institutionals and insiders believe in FARN or VRP?

Does the media prefer FARN or VRP?

Which has preferable valuation and earnings, FARN or VRP?

Summary

How does Faron Pharmaceuticals Oy compare to BTG?

Does the media prefer BTG or FARN?

Do institutionals and insiders hold more shares of BTG or FARN?

Do analysts rate BTG or FARN?

Which has stronger valuation and earnings, BTG or FARN?

Is BTG or FARN more profitable?

Summary

How does Faron Pharmaceuticals Oy compare to Arix Bioscience?

Which has more risk & volatility, FARN or ARIX?

Which has better valuation and earnings, FARN or ARIX?

Do insiders & institutionals believe in FARN or ARIX?

Is FARN or ARIX more profitable?

Does the media prefer FARN or ARIX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FARN vs. The Competition

Faron Pharmaceuticals Oy Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools